Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors

NCT04442126 is registered in ClinicalTrials.gov with Numab Therapeutics AG as lead sponsor.

NCT NCT04442126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Lead sponsor
Numab Therapeutics AG
Phase
Phase 1/2
Overall status
Terminated
Start date
August 19, 2020
Completion date
February 6, 2024
Enrollment
52 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colorectal cancer, fallopian tube cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian carcinoma, peritoneal carcinoma, squamous cell carcinoma, triple negative breast cancer